MT-UAVIONIX
24.3.2021 23:10:12 CET | Business Wire | Press release
uAvionix Corporation today announced it achieved DoD AIMS Mk XIIB certification of its first Identification Friend or Foe (IFF) transponder, the RT-2087/ZPX-B . With this certification, ZPX-B becomes the world’s smallest, certified micro-IFF transponder, reducing Size, Weight, and Power Consumption (SWaP) characteristics of typical IFF transponders by more than 90%, and at less than half the size, one-third the weight, and one fourth the power consumption of other Unmanned Aircraft Systems (UAS) targeted IFF solutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005976/en/
The certification, issued by the Department of Defense (DoD) Air Traffic Control Radar Beacon System Identification Friend or Foe Program Office (AIMS PO), attests to its IFF capability and its interoperability with military equipment fielded by NATO and its allied countries. Incorporation of IFF technology into small, tactical, and attritable platforms allows them full participation into the cross-troop, cross-service branch, and cross-nation collaboration and situational awareness that prevents fratricide.
The ZPX-B enables IFF capability for small and tactical Group 1-4 UAS, thanks to its record-breaking SWaP at 3.3 in3 , 60 grams, and power consumption of only 3.5 Watts. Transmitting at 54dBm, ZPX-B provides civil transponder modes A, C, S, and ADS-B Out, as well as military modes 1, 2, 3, and 5 Levels 1 and 2 – all individually configurable. ADS-B In functionality provides situational awareness and Detect and Avoid (DAA) capabilities to the host platform. Crypto compatibility complies with AIMS 04-900A Option B, which includes the KIV-77 and KIV-79.
Passive IFF Reception for Situational Awareness
In addition to the ZPX-B, uAvionix introduces the ZPX-R, a passive ADS-B and Mode 5 Level 2 receiver for ground-based, shipborne, or airborne reception for situational awareness and DAA capability. Mode 5 Level 2 encrypted squitters enable situational awareness in areas where Mode 5 interrogators are absent, increasing the scalability of deployment. ZPX-R can provide data in multiple formats, including Open Mission Systems (OMS) for incorporation into tactical displays or ACAS Xu or similar DAA processors.
Unclassified Integration, Testing, and Demonstration with Crypto Emulation
For military programs or OEMs looking to integrate a micro-IFF into their platforms, ZPX-B incorporates an internal crypto-emulator that enables development and test independent of COMSEC-controlled equipment subject to onerous handling requirements.
For more information on the uAvionix line of defense products, including IFF transponders, receivers, GPS, and crypto emulators, visit https://uavionix.com/defense/ .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005976/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cosylab Launches PlanOne™ Treatment Planning System for Particle Therapy8.6.2026 08:00:00 CEST | Press release
Cosylab today announced the commercial launch of PlanOne™, a treatment planning system for particle therapy, bringing physics-accurate, radiobiologically informed planning and a unified clinical workflow into a single environment. PlanOne™ is FDA 510(k) cleared. "PlanOne™ began with listening. Over the years, our work on control systems in radiation oncology has put us in direct, ongoing contact with medical physicists and clinical teams at some of the leading facilities in the world," said Mark Pleško, CEO of Cosylab. "Our partners have been clear on what matters most for particle therapy: physics accuracy they can defend, clinical confidence at the point of plan approval, and a platform built to grow with AI and adaptive workflows. We designed PlanOne™ around those three priorities, and we'll keep developing it together with the clinical community that helped shape it." Physics-accurate, radiobiologically informed planning PlanOne™ is built on a GPU-accelerated Monte Carlo dose engin
BitGo MENA Launches Regulated Electronic Trading, Delivering Full Suite Trading Services to the Region8.6.2026 06:00:00 CEST | Press release
BitGo MENA FZE (“BitGo MENA”), a subsidiary of BitGo Holdings, Inc. (NYSE: BTGO) (“BitGo”), the digital asset infrastructure company, today announced the launch of electronic trading in the Middle East and North African (MENA). With this launch, clients can now access a comprehensive trading solution combining BitGo MENA’s established over-the-counter (OTC) trading offering with institutional-grade electronic execution, all operating under BitGo MENA’s Broker-Dealer license from Dubai’s Virtual Assets Regulatory Authority (VARA). The launch further expands BitGo MENA’s regulated product suite under VARA’s oversight, marking another step in the region’s continued buildout of institutional digital asset infrastructure amid growing demand for integrated execution and custody solutions. “The Middle East and North Africa has quickly become one of the most exciting regions in the world for digital assets, with regulators, institutions, and innovators moving with real purpose,” said Mike Bels
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference5.6.2026 18:00:00 CEST | Press release
- ALYFTREK Phase 3 data on children with cystic fibrosis ages 2 to 5 with vanzacaftor/tezacaftor/deutivacaftor-responsive genotypes including F/F and F/MF shows 65% reached sweat chloride levels of <30 mmol/L; Vertex on track to initiate global regulatory submissions in first half of 2026 - - Long-term 96-week interim analyses from two open-label extension studies demonstrate positive safety and efficacy profile of ALYFTREK in people with cystic fibrosis ages 6 and older -- Phase 3 data on TRIKAFTA® in children 1 to <2 years also presented; Vertex has initiated global regulatory submissions - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® (vanzacaftor/tezacaftor/deutivacaftor) in children ages 2 to 5, as well as data from 96-week interim analyses of two open-label extension studies of ALYFTREK in children 6 to 11 years and people 12 years and older demonstrating
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi5.6.2026 13:00:00 CEST | Press release
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260605704506/en/ K Pro, Owkin's AI scientist for biology, powered by multimodal patient data for smarter biopharma decision making. Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership. During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built
DFNS Rebrands as the Core Banking Platform for Digital Assets5.6.2026 12:41:00 CEST | Press release
DFNS today announced a rebrand, marking its evolution from a wallet infrastructure to the first core banking platform for digital assets. The company is introducing a new logo, website, and market position as fintechs and institutions move their products and operations onchain. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603859127/en/ Banks, fintechs, asset managers, trading firms, payment providers, market infrastructures, and clearing houses have stopped asking how to "add crypto." They're asking how to run financial products, controls, workflows, and client services on blockchain rails, with the reliability expected of core infrastructure. Some are going further still, exploring whether the blockchain can serve as the ledger itself, where an account is an onchain object rather than a row in a database. Where IBANs, virtual accounts, and blockchain wallets converge into one governed financial account. “DFNS was built
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom